Table 2.

Complement, leukocytes, and albumin in controls, surviving and non-surviving necrotizing soft-tissue infection patients.

Variable	Total (N = 135)	Controls (N = 65)	NSTI survivors (N = 104)	NSTI non-survivors (N = 31)	p-value
MASP-1, AU/L	7.6 [6.5–8.9]	8.7 [7.5–10.2]ab	7.8 [6.8–9.0]cb	7.0 [5.8–8.0]ca	0.0003
MASP-2, AU/L	793.4 [504.1–1121.0]	977.5 [623.3–1464.3]b	874.5 [568.8–1182.5]b	551.9 [404.6–849.4]ca	0.0025
MASP-3, AU/L	65.4 [47.5–100.5]	109.3 [87.9–130.1]ab	64.3 [46.5–100.1]c	67.6 [56.6–104.8]c	<0.0001
C4, g/Ld	0.17 [0.14–0.24]	0.24 [0.20–0.31]ab	0.19 [0.15–0.26]cb	0.13 [0.11–0.17]ca	<0.0001
C4c AU/L	134.6 [87.3–199.0]	194.7 [130.9–326.5]ab	150.4 [96.2–210.3]cb	99.6 [69.8–158.9]ca	<0.0001
C4c/C4d	752.9 [507.1–1165.8]	855.3 [569.8–1391.0]	720.2 [496.5–1163.0]	791.5 [571.3–1250.6]	0.2793
C3, g/Ld	0.93 [0.75–1.2]	1.2 [1.1–1.4]ab	0.96 [0.79–1.2]cb	0.79 [0.56–0.98]ca	<0.0001
C3bc, AU/L	15.7 [9.2–24.2]14.7 [9.1–22.0]	12.5 [9.1–18.4]	15.2 [9.0–22.0]	17.7 [9.5–26.4]	0.1091
C3bc/C3d	16.5 [10.3–27.0]	10.7 [7.7, 14.7]ab	14.9 [9.8, 21.7]cb	24.3 [16.5, 40.6]ca	<0.0001
TCC, AU/L	1.5 [1.00–2.6]	0.35 [0.26–0.46]ab	1.5 [0.97–2.6]c	1.5 [1.1–2.7]c	<0.0001
Leukocyte count, × 10/l, highest value	16.9 [10.4–23.9]	7.2 [6.3–9.3]ab	16.5 [11.1–23.1]c	18.3 [8.5–27.2]c	<0.0001
C-reactive protein, mg/Ld	222.0 [141.0–298.0]	2.0 [1.00–4.0]ab	224.5 [169.0–306.5]cb	165.0 [83.0–259.0]ca	<0.0001
Albumin, g/L	20.0 [16.0–22.0]	39.0 [36.0–41.0]ab	20.0 [16.5–22.5]c	19.0 [15.0–21.0]c	<0.0001

Values presented as Median [IQR] with Kruskal-Wallis test. A significance level of 0.0167 was used for pairwise ad-hoc comparisons.

^aSignificantly different from NSTI survivors.

^bSignificantly different from NSTI non-survivors.

^cSignificantly different from controls.

^dData not available for all subjects. Missing values: C4 (n = 4), C4c/C4 (n = 4) C3 (n = 4), C3bc/c3 (n=4), leukocyte count (n = 3), and CRP (n = 4).

NSTI, necrotizing soft-tissue infection.